Free accessResearch articleFirst published online 2003-8
Age,Adherence and Injection Drug use Predict Virological Suppression among Men and Women Enrolled in a Population-Based Antiretroviral Drug Treatment Programme
To characterize 1-year virological response to antiretroviral therapy and its determinants by sex.
Methods
This is a population-based analysis of anti-retroviral therapy naive HIV-positive adult men and women. Factors associated with sex and with plasma HIV RNA viral load suppression to below 500 copies/ml were examined using non-parametric tests and logistic regression analyses.
Results
A total of 739 subjects (92 women and 647 men) were eligible. Female participants were younger (34 vs 37 years; P<0.001), less likely to have AIDS (6.5 vs 14.4%; P=0.039), more frequently injection drug users (44.6 vs 25.2%; P=0.001) and were less likely to be adherent to therapy (34.8 vs 62.9%; P<0.001) than male participants. There was no difference in baseline median CD4 count (P=0.424) or HIV RNA levels (P=0.140), physician experience (P=0.057), or with respect to antiretroviral regimens containing protease inhibitors or non-nucleoside reverse transcriptase inhibitors (P=0.911). With treatment, 46.7% (43/92) of women and 64.8% (419/647) of men (P=0.001) suppressed HIV RNA viral load to below 500 copies/ml at 1 year. In a multivariate analysis, the association of sex with HIV RNA response to antiretroviral therapy fell from statistical significance (odds ratio 1.18; 95% CI: 0.72–1.95) after adjusting for adherence, injection drug use and age.
Conclusion
Our data indicate that in this population-based setting, sex differences in 1-year virological response to antiretroviral therapy are explained by age, adherence and injection drug use.
References
1.
CarpenterC.C., CooperD.A., FischlM.A., GatellJ.M., GazzardB.G., HammerS.M.. Antiretroviral therapy in adults: updated recommendations of the International AIDS society – USA Panel. Journal of the American Medical Association2000; 283(3): 381–390.
2.
HoggR.S., YipB., KullyC., CraibK.J., O'ShaugnessyM.V., SchechterM.T., & MontanerJ.S.Improved survival among HIV-infected patients after initiation of triple-drug anti-retroviral regimens. Canadian Medical Association Journal1999; 160(5): 659–665.
3.
MontanerJ.S., MontessoriV., HarriganR., O.S.M., & HoggR.Antiretroviral therapy: ‘the state of the art’. Biomedicine & Pharmacotherapy1999; 53(2): 63–72.
4.
MellorsJ.W., MunozA., GiorgiJ.V., MargolickJ.B., TassoniC.J., GuptaP., KingsleyL.A., ToddJ.A., SaahA.J., DetelsR., PhairJ.P., & RinaldoC.R.Jr.. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Annals of Internal Medicine1997; 126(12): 946–954.
5.
FowlerM.G., MelnickS.L., & MathiesonB.J.Women and HIV. Epidemiology and global overview. Obstetrics & Gynecology Clinics of North America1997; 24(4): 705–729.
6.
SterlingT.R., LylesC.M., VlahovD., AstemborskiJ., MargolickJ.B., & QuinnT.C.Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. Journal of Infectious Diseases1999; 180(3): 666–672.
7.
SterlingT.R., VlahovD., AstemborskiJ., HooverD.R., MargolickJ.B., & QuinnT.C.Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. New England Journal of Medicine2001; 344(10): 720–725.
8.
MoroniM.Sex differences in HIV-1 viral load and progression to AIDS. Lancet1999; 353(9152): 589–590.
9.
JunghansC., LedergerberB., ChanP., WeberR., & EggerM.Sex differences in HIV-1 viral load and progression to AIDS. Lancet1999; 353(9152): 589.
10.
KatzensteinD.A., HammerS.M., HughesM.D., GundackerH., JacksonJ.B., FiscusS., RasheedS., ElbeikT., ReichmanR., JapourA., & MeriganT.C.The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. New England Journal of Medicine1996; 335(15): 1091–1098.
11.
FarzadeganH., HooverD.R., AstemborskiJ., LylesC.M., MargolickJ.B., MarkhamR.B., QuinnT.C., & VlahovD.Sex differences in HIV-1 viral load and progression to AIDS. Lancet1998; 352(9139): 1510–1514.
12.
EvansJ.S., NimsT., CooleyJ., BradleyW., JagodzinskiL., ZhouS., MelcherG.P., BurkeD.S., & VaheyM.Serum levels of virus burden in early stage human immunodeficiency virus type 1 disease in women. Journal of Infectious Diseases1997; 175(4): 795–800.
13.
DelmasM.C., JadandC., De VincenziI., DeveauC., PersozA., SobelA., KazatchkineM., BrunetJ.B., & MeyerL.Gender difference in CD4+ cell counts persist after HIV-1 infection. AIDS1997; 11(8): 1071–1073.
14.
PrinsM., RobertsonJ.R., BrettleR.P., AguadoI.H., BroersB., BoufassaF., GoldbergD.J., ZangerleR., CoutinhoR.A., & van den HoekA.Do gender differences in CD4 cell counts matter?AIDS1999; 13(17): 2361–2364.
15.
MelnickS.L., ShererR., LouisT.A., HillmanD., RodriguezE.M., LackmanC., CappsL., BrownL.S.Jr., CarlynM., & KorvickJ.A.Survival and disease progression according to gender of patients with HIV Infection. The Terry Beirn Community Programs for Clinical Research on AIDS. Journal of the American Medical Association1994; 272(24): 1915–1921.
16.
Cozzi LepriA., PezzottiP., DorrucciM., PhillipsA.N., & RezzaG.HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. British Medical Journal1994; 309(6968): 1537–1542.
17.
ChaissonR.E., KerulyJ.C., & MooreR.D.Race, sex, drug use, and progression of human immunodeficiency virus disease. New England Journal of Medicine1995; 333(12): 751–756.
18.
MooreR.D., CheeverL., KerulyJ.C., & ChaissonR.E.Lack of sex difference in CD4 to HIV-1 RNA viral load ratio. Lancet1999; 353(9151): 463–464.
19.
BushC.E., DonovanR.M., MarkowitzN., BaxaD., KvaleP., & SaravolatzL.D.Gender is not a factor in serum human immunodeficiency virus type 1 RNA levels in patients with viremia. Journal of Clinical Microbiology1996; 34(4): 970–972.
20.
EllerbrockT.V., BushT.J., ChamberlandM.E., & OxtobyM.J.Epidemiology of women with AIDS in the United States, 1981 through 1990. A comparison with heterosexual men with AIDS. Journal of the American Medical Association1991; 265(22): 2971–2975.
21.
ZorillaC.D.Antiretroviral combination therapy in HIV-1 infected women and men: are their responses different?International Journal of Fertility2000; 45: 195–199.
22.
GerstenM., ChapmanS., FarnsworthA., ChangY., YuG., & ClendeninnN.The safety and efficacy of Viracept (nelfinavir mesylate, NFV) in female patients participated in pivotal Phase II/III double-blind randomized controlled trials. Conference on Women & HIV. Pasadena, Calif., USA, May 4–7, 1997; 1.
23.
LeavittR., LewiD.S., UipD., PedroR., KalichmanA., & SuleimanJ.Subgroup analysis of clinical and surrogate marker efficacy by gender in a study of indinavir (IDV) alone and zidovudine (ZDV) in treatment naive HIV-1 patients with 50–250 CD4 cells/mm3.12th World AIDS Conference. Geneva, Switzerland, June 28–July 3 1998; 60358.
24.
SquiresK., GulickR., PaviaA., EronJ., MurphyR., MauneyJ.. Sex differences in the selection of thymidine analog regimen therapy trials (START I and START II).7th Conference on Retroviruses & Opportunistic Infections. Geneva, Switzerland, 2000.
25.
LempG.F., HirozawaA.M., CohenJ.B., DerishP.A., McKinneyK.C., & HernandezS.R.Survival for women and men with AIDS. Journal of Infectious Diseases1992; 166(1): 74–79.
26.
MontanerJ., & O'ShaugnessyM.Therapeutic Guidelines for the Treatment of HIV/AIDS and Related Conditions. Vancouver: BC Centre for Excellence in HIV/AIDS; 1996.
27.
CarpenterC.C., FischlM.A., HammerS.M., HirschM.S., JacobsenD.M., KatzensteinD.A., MontanerJ.S., RichmanD.D., SaagM.S., SchooleyR.T., ThompsonM.A., VellaS., YeniP.G., & VolberdingP.A.Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society–USA panel. Journal of the American Medical Association1997; 277(24): 1962–1969.
28.
CarpenterC.C., FischlM.A., HammerS.M., HirschM.S., JacobsenD.M., KatzensteinD.A., MontanerJ.S., RichmanD.D., SaagM.S., SchooleyR.T., ThompsonM.A., VellaS., YeniP.G., & VolberdingP.A.Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society–USA Panel. Journal of the American Medical Association1998; 280(1): 78–86.
29.
World Health Organization. Acquired immune deficiency syndrome (AIDS): interim proposal for a WHO staging system for HIV infection and disease. Weekly Epidemiological Record1990; 65: 221–228.
30.
CarpenterC.C., FischlM.A., HammerS.M., HirschM.S., JacobsenD.M., KatzensteinD.A., CarpenterC.C., FischlM.A., HammerS.M., HirschM.S., JacobsenD.M., KatzensteinD.A., MontanerJ.S., RichmanD.D., SaagM.S., SchooleyR.T., ThompsonM.A., VellaS., YeniP.G., & VolberdingP.A.Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society–USA. Journal of the American Medical Association1996; 276(2): 146–154.
31.
Low-BeerS., YipB., O'ShaugnessyM.V., HoggR.S., & MontanerJ.S.G.Adherence to triple therapy and viral load response. Journal of Acquired Immune Deficiency Syndromes2000; 23: 360–361.
32.
PatersonD.L., SwindellsS., MohrJ., BresterM., VergisE.N., SquierC., WagenerM.M., & SinghN.Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine2000; 133(1): 21–30.
33.
KitahataM.M., Van RompaeyS.E., & ShieldsA.W.Physician experience in the care of HIV-infected persons is associated with earlier adoption of new antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes2000; 24(2): 106–114.
34.
PhillipsA.N., StaszewskiS., WeberR., KirkO., FrancioliP., MillerV., VernazzaP., LundgrenJ.D., & LedergerberB. for the Swiss HIV Cohort Study, the Frankfurt HIV Clinic Cohort, and the EuroSIDA Study Group. HIV viral load response to antiretroviral therapy according to baseline CD4 cell count and viral load. Journal of the American Medical Association2001; 286: 2560–2567.
35.
LedergerberB., EggerM., OpravilM., TelentiA., HirshelB., BattegayM., VernazzaP., SudreP., FleppM., FurrerH., FrancioliP., & WeberR., for the Swiss HIV Cohort Study. Clinical Progression and virologic failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet1999; 353: 863–868.
36.
KalishL.A., CollierA.C., FlaniganT.P., & KumarP.Plasma viral load in women and men with advanced HIV disease.39th Interscience Conference on Antimicrobial Agents & Chemotherapy. San Francisco, Calif., USA, September 26–29 1999.
37.
Collaborative Group on AIDS Incubation & HIV Survival.Time from HIV-1 seroconversion to AIDS and death before widespread use of highly active antiretroviral therapy: a collaborative re-analysis. Lancet2000; 355: 1131–1137.
38.
PalellaF.J.Jr., DelaneyK.M., MoormanA.C., LovelessM.O., FuhrerJ., SattenG.A., AschmanD.J., & HolmbergS.D.Declining morbidity and mortality among patients with advanced human immunodeficiency virus. New England Journal of Medicine1998; 338(13): 853–860.
39.
ThurmannP.A., & HompeschB.C.Influence of gender on the phamacokinetics and pharmacodynamics of drugs. International Journal of Clinical Pharmacology & Therapeutics1998; 36(11): 586–590.
40.
HaderS., SmithD., MooreJ., & HolmbergS.HIV infection in women in the United States: status at the millenium. Journal of the American Medical Association2001; 285: 1186–1192.
41.
MuseyL., HughesJ., SchackerT., SheaT., CoreyL., & McElrathM.J.Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. New England Journal of Medicine1997; 337(18): 1267–1274.
42.
RayS.C., & QuinnT.C.Sex and the genetic diversity of HIV-1. Nature Medicine2000; 6(1): 23–25.
43.
LongE.M., MartinH.L.Jr., KreissJ.K., RainwaterS.M., LavreysL., JacksonD.J., RakwarJ., & MandaliyaK.Gender differences in HIV-1 diversity at time of infection. Nature Medicine2000; 6(1): 71–75.
44.
MehtaS., MooreR.D., & GrahamN.M.Potential factors affecting adherence with HIV therapy. AIDS1997; 11(14): 1665–1670.
45.
GordilloV., del AmoJ., SorianoV., & Gonzalez-LahozJ.Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS1999; 13(13): 1763–1769.
46.
Rodriguez-RosadoR., Jimenez-NacherI., SorianoV., AntonP., & Gonzalez-LahozJ.Virological failure and adherence to antiretrovial therapy in HIV-infected patients. AIDS1998; 12(9): 1112–1113.
47.
GrossR., BilkerW.B., FriedmanH.M., & StromB.L.Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS2001; 15(16): 2109–2117.
48.
MillerL., & HaysR.Adherence to combination antiretroviral therapy: synthesis of the literature and clinical implications. The AIDS Reader2000; 10(3): 177–185.
49.
AlexanderC.S., DongW., SchechterM.T., O'ShaugnessyM.V., StrathdeeS.A., MoT., MontanerJ.S.G., & HarriganP.R.Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV among injection drug users. AIDS1999; 13(8): 981–985.
50.
PalepuA., StrathdeeS.A., HoggR.S., AnisA.H., RaeS., CornelisseP.G., PatrickD.M., O'ShaughnessyM.V., & SchechterM.T.The social determinants of emergency department and hospital use by injection drug users in Canada. Journal of Urban Health1999; 76(4): 409–418.
51.
MooreA.L., SabinC.A., JohnsonM.A., & PhillipsA.N.Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study. Journal of Acquired Immune Deficiency Syndromes2002; 29(2): 197–202.
52.
MooreR.D., FortgangI., KerulyJ., & ChaissonR.E.Adverse events from drug therapy for human immunodeficiency disease. American Journal of Medicine1996; 101(1): 34–40.
53.
IckovicsJ.R., HamburgerM.E., VlahovD., SchoenbaumE.E., SchumanP., BolandR.J., & MooreJ.; HIV Epidemiology Research Study Group. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. Journal of the American Medical Association2001; 285(11): 1466–1474.
